FluidForm Bio reports Form D offering with $1.7 million raised so far
The Waltham, Massachusetts biotechnology company disclosed a $3 million equity offering, of which $1,703,371 has been sold to 20 investors as of the filing.
FluidForm Bio, Inc. filed a Form D notice with the Securities and Exchange Commission dated August 27, 2026, disclosing an exempt securities offering. The company is based at 852 Winter St. in Waltham, Massachusetts.1
The total offering amount is listed as $3,000,000, with $1,703,371 already sold and $1,296,629 remaining to be sold.1 Twenty investors have already put money into the offering.1 The date of first sale was listed as July 16, 2026.1
The filing states this is not a transaction of the kind described in the form as a merger, acquisition or exchange offer. The securities offered include equity as well as an option, warrant or other right to acquire another security.1 The minimum investment accepted from any outside investor is listed as $0.1
The company claimed exemption under Rule 506(b) of Regulation D.1 No sales commissions or finders' fees were reported, both listed as $0.1 Proceeds directed to executives, directors or promoters named in the filing were also listed as $0.1
The related persons named in the filing are Michael Graffeo, President and Chief Executive Officer; Adam Feinberg, Chief Technology Officer; and Erik Waters, Chief Financial Officer, all listed at the same Waltham address.1 The filing categorizes FluidForm Bio's industry as biotechnology.1 The company declined to disclose its revenue range or aggregate net asset value.1
The company indicated it does not intend the offering to last more than one year.1 The notice was signed electronically by Michael Graffeo as President and CEO on August 27, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.